Breast	200	Trastuzumab (IV) Monotherapy 21 days
Breast	201	Trastuzumab (IV) Monotherapy 7 days
Breast	202	DOCEtaxel Monotherapy 100mg/m2 – 21 day cycle
Breast	203	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle
Breast	204	Pertuzumab + Trastuzumab + DOCEtaxel
Breast	205	Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX) ® 28 days
Breast	206	Trastuzumab Emtansine (Kadcyla®) - 21 days
Breast	212	Bevacizumab 10mg/kg-14days
Breast	215	Bevacizumab 15mg/kg - 21 days
Breast	216	Capecitabine Monotherapy
Breast	217	Lapatinib and Capecitabine
Breast	226	PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day
Breast	228	EriBULlin Monotherapy
Breast	230	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle
Breast	232	Intravenous Vinorelbine Monotherapy-21day
Breast	250	DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day
Breast	251	CARBOplatin (AUC4-6) Monotherapy-28 days
Breast	252	DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day
Breast	253	Tamoxifen Monotherapy
Breast	254	Anastrozole Monotherapy
Breast	258	DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days
Breast	259	Oral Vinorelbine Monotherapy-7days
Breast	260	DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)
Breast	261	CARBOplatin (AUC4-6) Monotherapy-21 days
Breast	262	epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day
Breast	263	epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day
Breast	265	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy
Breast	269	5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy
Breast	272	Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma
Breast	278	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)
Breast	285	Trastuzumab SC 21 days-Early Breast Cancer
Breast	316	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)
Breast	322	Everolimus and Exemestane Therapy
Breast	348	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy
Breast	350	pertuzumab and trastuzumab and chemotherapy -21 day cycles
Breast	361	Fulvestrant Therapy
Breast	371	Letrozole Monotherapy
Breast	376	Exemestane Monotherapy
Breast	377	Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy
Breast	378	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy
Breast	381	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy
Breast	414	Palbociclib Therapy-28 day
Breast	423	DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle
Breast	430	Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days
Breast	432	DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)
Breast	433	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)
Breast	485	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)
Breast	507	Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle
Breast	512	PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)
Breast	525	Ribociclib Therapy-28 day
Breast	526	Pertuzumab Trastuzumab and VinORELBine
Breast	545	Zoledronic acid monotherapy
Breast	605	Talazoparib Therapy
Breast	621	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day
Breast	659	Trastuzumab Emtansine (Kadcyla®) Early Breast Cancer Therapy- 21 days
Breast	688	Atezolizumab and nab-PACLitaxel Therapy
Breast	726	Pertuzumab and Trastuzumab Therapy
Breast	722	DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy
Breast	731	DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy
Breast	736	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle
Breast	738	Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy
Breast	743	eriBULin Monotherapy – 28 Day
Breast	745	Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)
Breast	775	Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)
Breast	785	Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy
Breast	789	DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy
Breast	790	Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)
Breast	796	Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle
Breast	797	Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle
Gastrointestinal	203	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle
Gastrointestinal	207	Cetuximab Monotherapy-7 days
Gastrointestinal	209	Modified FOLFOX-6 Therapy-14 day
Gastrointestinal	210	FOLFOX-4 Therapy-14 day
Gastrointestinal	212	Bevacizumab 10mg/kg-14days
Gastrointestinal	213	Irinotecan Monotherapy - 21 days
Gastrointestinal	214	Bevacizumab 7.5mg/kg-21days
Gastrointestinal	215	Bevacizumab 15mg/kg - 21 days
Gastrointestinal	216	Capecitabine Monotherapy
Gastrointestinal	225	Panitumumab 6mg/kg Therapy
Gastrointestinal	226	PACLitaxel Monotherapy 80mg/m2 7day
Gastrointestinal	227	FOLFIRI Therapy-14 day
Gastrointestinal	235	CISplatin and Teysuno-28 day cycle
Gastrointestinal	238	Aflibercept-14 days
Gastrointestinal	239	epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy
Gastrointestinal	240	epiRUBicin, CISplatin and 5-FU (ECF) Therapy
Gastrointestinal	244	Regorafenib Monotherapy
Gastrointestinal	256	Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day
Gastrointestinal	283	Gemcitabine (1000mg/m2) Monotherapy - 56 day
Gastrointestinal	284	Gemcitabine (1000mg/m2) Monotherapy - 28 day
Gastrointestinal	294	Sorafenib Therapy
Gastrointestinal	321	Capecitabine/Oxaliplatin (XELOX) Therapy
Gastrointestinal	328	FOLFIRI (14 days)+ Cetuximab (7 days) Therapy
Gastrointestinal	329	FOLFIRINOX Therapy
Gastrointestinal	330	Cetuximab (7 days) and Irinotecan (14 days) Therapy
Gastrointestinal	331	Cetuximab (14 days) and Irinotecan (14 days) Therapy
Gastrointestinal	344	FLOT Therapy-14 day
Gastrointestinal	380	epiRUBicin, CISplatin and Capecitabine (ECX) Therapy
Gastrointestinal	382	Trifluridine and Tipiracil (Lonsurf®) Therapy
Gastrointestinal	383	Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day
Gastrointestinal	384	Gemcitabine + Capecitabine Therapy
Gastrointestinal	386	DOXOrubicin (60mg/m2) Therapy
Gastrointestinal	421	5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion 7 day
Gastrointestinal	422	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks
Gastrointestinal	427	Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen / Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen
Gastrointestinal	428	QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly
Gastrointestinal	429	epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day
Gastrointestinal	446	Bevacizamab 5mg/kg and Modified FOLFOX-6 Therapy-14 day
Gastrointestinal	447	Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day
Gastrointestinal	448	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day
Gastrointestinal	449	Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days
Gastrointestinal	451	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy
Gastrointestinal	460	CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen
Gastrointestinal	473	CISplatin and Capecitabine Adjuvant Chemoradiation Therapy
Gastrointestinal	486	FLOX Therapy
Gastrointestinal	502	Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days
Gastrointestinal	505	Capecitabine and Temozolomide Therapy*
Gastrointestinal	509	Modified FOLFOX-6 Chemoradiation Therapy-14 day
Gastrointestinal	515	Modified FOLFIRINOX Therapy
Gastrointestinal	521	Gemcitabine (1000mg/m2) and RT therapy
Gastrointestinal	522	Gemcitabine (400mg/m2) and RT therapy
Gastrointestinal	523	Capecitabine and RT – 7 day
Gastrointestinal	524	Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days
Gastrointestinal	555	FOLFOXIRI Therapy
Gastrointestinal	559	Gemcitabine (600mg/m2) and RT therapy
Gastrointestinal	585	FOLFIRI (14 days)+ Cetuximab (14 days) Therapy
Gastrointestinal	586	Capecitabine 825mg/m2 and RT–7 day
Gastrointestinal	594	CISplatin, Infusional 5-Fluorouracil and Radiation Therapy
Gastrointestinal	621	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day
Gastrointestinal	623	Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day Therapy- 21 day
Gastrointestinal	644	Lenvatinib -HCC Therapy
Gastrointestinal	654	Irinotecan 150mg/m2 Monotherapy - 28 days
Gastrointestinal	660	5-Fluorouracil and Folinic Acid Therapy-14 day
Gastrointestinal	691	FOLFIRINOX Therapy - (Rectal Carcinoma)
Gastrointestinal	692	Cetuximab and FOLFOX-4 Therapy
Gastrointestinal	704	Trastuzumab and FOLFOX-6 Modified Therapy-14 day
Gastrointestinal	727	mitoMYcin and Capecitabine Chemoradiation Therapy
Gastrointestinal	732	Cetuximab Therapy-14 days
Gastrointestinal	733	Cetuximab and FOLFOX-6 (modified) Therapy
Gastrointestinal	783	Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days
Genitourinary	101	Cabazitaxel and Prednisolone
Genitourinary	103	Abiraterone and Prednisolone Therapy
Genitourinary	104	Axitinib Monotherapy
Genitourinary	203	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle
Genitourinary	212	Bevacizumab 10mg/kg-14days
Genitourinary	226	PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day
Genitourinary	233	Enzalutamide Monotherapy
Genitourinary	257	Radium 223 Therapy
Genitourinary	282	Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day
Genitourinary	294	Sorafenib Therapy
Genitourinary	310	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day
Genitourinary	313	DOCEtaxel Monotheray 50mg/m2 Monotherapy-14 day
Genitourinary	320	Everolimus Monotherapy
Genitourinary	325	Sunitinib 50mg Therapy
Genitourinary	326	Temsirolimus Monotherapy
Genitourinary	333	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy
Genitourinary	337	CISplatin, Methotrexate and Vinblastine Therapy
Genitourinary	338	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days
Genitourinary	385	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)
Genitourinary	437	TICE -Autologous Conditioning Germ Cell Tumour Regimen
Genitourinary	445	Pazopanib Therapy
Genitourinary	450	5-Fluorouracil and mitoMYcin Chemoradiation Therapy
Genitourinary	453	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen
Genitourinary	455	Pembrolizumab 200mg Monotherapy
Genitourinary	477	Goserelin 10.8mg-12 Weekly Therapy
Genitourinary	478	Goserelin 3.6mg Therapy- 4 weeks
Genitourinary	479	Leuprorelin 22.5mg Therapy- 12 weeks
Genitourinary	480	Triptorelin 11.25mg Therapy- 12 weeks
Genitourinary	481	Degarelix Therapy- 28 day
Genitourinary	482	Bicalutamide Therapy
Genitourinary	483	Nivolumab Monotherapy 240mg-14 day
Genitourinary	484	Nivolumab Monotherapy 480mg-28day
Genitourinary	488	Triptorelin 22.6mg Therapy- 24 weeks
Genitourinary	489	Triptorelin 3mg Therapy- 28 day
Genitourinary	490	Leuprorelin 7.5mg Therapy- 28 day
Genitourinary	491	Leuprorelin 45mg Therapy- 24 week
Genitourinary	492	Leuprorelin 11.25mg Therapy- 12 weeks
Genitourinary	493	Leuprorelin 30mg Therapy- 24 weeks
Genitourinary	494	Leuprorelin 3.75mg Therapy-28 day
Genitourinary	518	Cabozantanib Therapy
Genitourinary	544	Atezolizumab 1200mg Monotherapy
Genitourinary	546	DOCEtaxel 75mg/m2 - Prednisolone combination therapy
Genitourinary	551	Nivolumab 3mg Ipilimumab 1mg Therapy
Genitourinary	558	Pembrolizumab 400mg Monotherapy
Genitourinary	564	Tivozanib Therapy
Genitourinary	574	Apalutamide therapy
Genitourinary	577	Abiraterone 1000mg and Prednisolone 5mg Therapy
Genitourinary	583	Pembrolizumab 200mg and Axitinib Therapy
Genitourinary	593	Atezolizumab 1680mg Monotherapy – 28 Day
Genitourinary	592	Atezolizumab Monotherapy-14 day
Genitourinary	621	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day
Genitourinary	622	Gemcitabine (1000mg/m2 ) and CISplatin (35mg/m2 ) Therapy- 21 day
Genitourinary	628	Gemcitabine (1000mg/m2 ) and CISplatin (70mg/m2 ) Therapy- 21 day
Genitourinary	719	SUNitinib 50mg Therapy (21 days)
Gynaecology	203	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle
Gynaecology	205	Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX) ® 28 days
Gynaecology	212	Bevacizumab 10mg/kg-14days
Gynaecology	215	Bevacizumab 15mg/kg - 21 days
Gynaecology	226	PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day
Gynaecology	232	Intravenous Vinorelbine Monotherapy-21day
Gynaecology	246	Methotrexate 8 day Charing Cross Regimen
Gynaecology	247	DACTINomycin Therapy
Gynaecology	248	EMA/CO Therapy
Gynaecology	249	Intrathecal Methotrexate for CNS Prophylaxis in GTN
Gynaecology	251	CARBOplatin (AUC4-6) Monotherapy-28 days
Gynaecology	261	CARBOplatin (AUC4-6) Monotherapy-21 days
Gynaecology	264	Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy
Gynaecology	266	PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy
Gynaecology	267	Two Day Etoposide CISplatin (EP) Therapy
Gynaecology	303	CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy
Gynaecology	306	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day
Gynaecology	308	CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy
Gynaecology	311	Topotecan Monotherapy-5 day
Gynaecology	312	Topotecan Monotherapy-Weekly
Gynaecology	375	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy
Gynaecology	385	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)
Gynaecology	419	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)
Gynaecology	499	Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day
Gynaecology	588	Olaparib (Tablet) Monotherapy
Gynaecology	571	Niraparib Monotherapy
Gynaecology	620	Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy
Gynaecology	621	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day
Gynaecology	624	Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day
Gynaecology	676	CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer
Gynaecology	716	Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLItaxel 175mg/m2
Gynaecology	766	Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy
Gynaecology	769	Bevacizumab 10mg/kg and PACLItaxel 80mg/m2 (day 1,8,15,22) Therapy
Gynaecology	771	Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy
Gynaecology	772	Bevacizumab 10mg/kg and Pegylated DOXOrubicin (CAELYX) 40mg/m2 therapy
Head & Neck	207	Cetuximab Monotherapy-7 days
Head & Neck	242	Vandetanib Monotherapy
Head & Neck	294	Sorafenib Therapy
Head & Neck	295	Lenvatinib -DTC Therapy
Head & Neck	314	CISplatin and 5-Fluorouracil Therapy-28 day
Head & Neck	315	Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery
Head & Neck	323	DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy
Head & Neck	324	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy
Head & Neck	332	CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days
Head & Neck	385	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)
Head & Neck	387	CISplatin (100mg/m2) with Radiotherapy (RT)
Head & Neck	417	Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 day cycle
Head & Neck	418	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle
Head & Neck	419	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)
Head & Neck	483	Nivolumab Monotherapy 240mg-14 day
Head & Neck	484	Nivolumab Monotherapy 480mg-28day
Head & Neck	514	Gemcitabine (1250mg/m2) Monotherapy - 21 day
Head & Neck	517	Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day
Head & Neck	552	CARBOplatini (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle
Head & Neck	558	Pembrolizumab 400mg Monotherapy
Head & Neck	589	CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy
Head & Neck	591	CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy
Head & Neck	615	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day
Leukaemia/BMT	224	Bosutinib Monotherapy
Leukaemia/BMT	229	Ruxolitinib Monotherapy
Leukaemia/BMT	231	Decitabine Monotherapy – AML (28 day cycle)
Leukaemia/BMT	234	Brentuximab vedotin Monotherapy
Leukaemia/BMT	241	Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy
Leukaemia/BMT	286	Obinutuzumab and Chlorambucil Therapy
Leukaemia/BMT	287	Azacitidine 75mg/m2 5-2-2 Therapy
Leukaemia/BMT	288	Azacitidine 100mg/m2 5-day Therapy
Leukaemia/BMT	302	Ponatinib Therapy
Leukaemia/BMT	356	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy
Leukaemia/BMT	357	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy
Leukaemia/BMT	359	DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)
Leukaemia/BMT	360	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)
Leukaemia/BMT	362	FLAG:Ida 8mg/m2 Therapy
Leukaemia/BMT	364	Intermediate Dose Cytarabine Therapy
Leukaemia/BMT	365	High Dose Cytarabine Therapy
Leukaemia/BMT	366	Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy
Leukaemia/BMT	389	Idelalisib and riTUXimab Therapy
Leukaemia/BMT	400	Venetoclax Monotherapy
Leukaemia/BMT	402	Cladribine 0.14mg/kg Day 1 to 5 Therapy
Leukaemia/BMT	410	Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy
Leukaemia/BMT	411	Chlorambucil10mg/m2 Therapy
Leukaemia/BMT	469	Cladribine 0.14mg/kg Weekly Therapy
Leukaemia/BMT	527	Bendamustine Monotherapy
Leukaemia/BMT	537	Inotuzumab ozogamicin Monotherapy
Leukaemia/BMT	538	Blinatumomab Therapy
Leukaemia/BMT	575	Venetoclax and Rituximab therapy
Leukaemia/BMT	590	Blinatumomab Therapy (ALL with MRD>0.1%
Leukaemia/BMT	612	Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML inducation)
Leukaemia/BMT	613	Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction Therapy
Leukaemia/BMT	618	Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation Therapy
Lung	203	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle
Lung	214	Bevacizumab 7.5mg/kg-21days
Lung	215	Bevacizumab 15mg/kg - 21 days
Lung	219	Erlotinib Monotherapy
Lung	220	Gefitinib Monotherapy
Lung	221	Afatinib Monotherapy
Lung	222	PEMEtrexed Monotherapy
Lung	226	PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day
Lung	232	Intravenous Vinorelbine Monotherapy-21day
Lung	243	Crizotinib Monotherapy
Lung	259	Oral Vinorelbine Monotherapy-7days
Lung	271	CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day
Lung	279	CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 day
Lung	280	CISplatin (75mg/m2) + Etoposide Therapy-21 day
Lung	281	Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day
Lung	284	Gemcitabine (1000mg/m2) Monotherapy - 28 day
Lung	304	CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy
Lung	309	Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy
Lung	310	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day
Lung	311	Topotecan Monotherapy-5 day
Lung	317	PEMEtrexed and CISplatin Therapy
Lung	318	PEMEtrexed and CARBOplatin Therapy
Lung	319	CARBOplatin and Oral Etoposide Therapy-21 days
Lung	339	Vinorelbine and CISplatin Therapy-21 days
Lung	340	Ceritinib Monotherapy
Lung	343	Vinorelbine and CISplatin Therapy-28 days
Lung	372	Nindetanib Therapy
Lung	388	Oral Etoposide Therapy
Lung	401	Alectinib Monotherapy
Lung	455	Pembrolizumab 200mg Monotherapy
Lung	456	CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day
Lung	483	Nivolumab Monotherapy 240mg-14 day
Lung	484	Nivolumab Monotherapy 480mg-28day
Lung	544	Atezolizumab 1200mg Monotherapy
Lung	558	Pembrolizumab 400mg Monotherapy
Lung	561	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day
Lung	562	Brigatinib Therapy
Lung	565	Dacomitinib Monotherapy
Lung	568	Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy
Lung	569	Pembrolizumab, PEMEtrexed and CISplatin Therapy
Lung	570	Lorlatinib therapy
Lung	579	Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy
Lung	587	Topotecan Oral Monotherapy
Lung	576	Durvalumab 10mg/kg Monotherapy-14 Day
Lung	593	Atezolizumab 1680mg Monotherapy – 28 Day
Lung	353	Osimertinib Monotherapy
Lung	614	CARBOplatin and vinORELbine Therapy-21 Day
Lung	592	Atezolizumab Monotherapy-14 day
Lung	621	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day
Lung	655	Durvalumab 1500mg Monotherapy-28 Day
Lung	689	Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy
Lung	702	Entrectinib Therapy
Lymphoma	234	Brentuximab vedotin Monotherapy
Lymphoma	255	Pixantrone Therapy
Lymphoma	277	Siltuximab Monotherapy
Lymphoma	290	ABVD Therapy
Lymphoma	291	Idelalisib Monotherapy
Lymphoma	293	(*riTUXimab), Cyclophosphamide VinCRIStine and Prednisolone (*R)-CVP) Therapy– 21 days
Lymphoma	297	Ibrutinib Therapy (Mantly Cell Lymphoma)
Lymphoma	307	(R*)-CHOP – 21 days
Lymphoma	345	riTUXimab and Bendamustine Therapy
Lymphoma	354	Escalated Dose BEACOPP 21 day Therapy
Lymphoma	355	Dose Adjusted R-EPOCH Therapy
Lymphoma	393	Nordic Therapy
Lymphoma	394	(R*)- ESHAP Therapy
Lymphoma	395	(R**)-DHAP Therapy
Lymphoma	396	CHOEP Therapy– 21 days
Lymphoma	397	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy
Lymphoma	398	R-CODOX-M Therapy (Patients less than or equal to 65 years)
Lymphoma	399	R-IVAC Therapy (Patients less than or equal to 65 years)
Lymphoma	403	R-CODOX-M Therapy (Patients greater than 65 years)
Lymphoma	404	R-IVAC Therapy (Patients greater than 65 years)
Lymphoma	407	SMILE Therapy (NK or T-cell lymphoma)
Lymphoma	408	BEAM Autologous Transplant Conditioning Protocol
Lymphoma	409	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRIStine and Prednisolone (*R)-CHOP Therapy– 14 days
Lymphoma	411	Chlorambucil10mg/m2 Therapy
Lymphoma	424	Obinutuzumab and Bendamustine Therapy-28 day cycle
Lymphoma	425	Obinutuzumab Maintenance Therapy -56 day
Lymphoma	436	(R**)- miniCHOP Therapy – 21 days
Lymphoma	441	riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)
Lymphoma	454	High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant
Lymphoma	455	Pembrolizumab 200mg Monotherapy
Lymphoma	466	riTUXimab-HyperCVAD Therapy (MCL) – Part A
Lymphoma	467	riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B
Lymphoma	468	LEAM Autologous Transplant Conditioning Protocol
Lymphoma	483	Nivolumab Monotherapy 240mg-14 day
Lymphoma	484	Nivolumab Monotherapy 480mg-28day
Lymphoma	506	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day
Lymphoma	508	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy
Lymphoma	510	R-CEOP Therapy – 21 days
Lymphoma	529	Brentuximab vedotin and Bendamustine Therapy
Lymphoma	530	Brentuximab vedotin and ESHAP therapyi (BRESHAP)
Lymphoma	532	Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy
Lymphoma	540	RiTUXimab 375 mg/m2 Maintenance Therapy-84 day
Lymphoma	541	RiTUXimab 375 mg/m2 Therapy-7 day
Lymphoma	542	riTUXimab 375 mg/m2 Combination Therapy-21 day
Lymphoma	543	RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day
Lymphoma	549	Obinutuzumab and CHOP Therapy – 21 day
Lymphoma	550	obinutuzumab and CVP therapy -21 days
Lymphoma	558	Pembrolizumab 400mg Monotherapy
Lymphoma	528	Brentuximab vedotin and ICE Therapy
Lymphoma	307.1	Cyclophosphamide, DOXOrubicin, vinCRIStine and prednisoLONE (CHOP) Therapy– 21 days
Lymphoma	599	RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day
Lymphoma	600	RiTUXimab (S/C 1400mg) Maintenance Therapy-56 day
Lymphoma	664	riTUXimab, Methotrexate, Procarbazine and vinCRIStine (R-MPV) – 14 Days Induction Therapyi
Lymphoma	666	High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day Therapy
Lymphoma	667	riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRIStine and Prednisolone (R-CHOP) Therapy– 21 Days
Lymphoma	672	Dose Adjusted R (S/C)-EPOCH Therapy
Lymphoma	685	Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy
Lymphoma	708	Zanubrutinib Therapy
Lymphoma	737	(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRIStine and PrednisoLONE (*R)-GCVP) Therapy–21 days
Lymphoma	801	Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) Therapy
Myeloma	218	Lenalidomide 25mg and Dexamethasone Therapy - 28 day
Myeloma	245	Pomalidomide and Dexamethasone
Myeloma	270	Bortezomib and Dexamethasone Therapy
Myeloma	273	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy
Myeloma	274	Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy
Myeloma	275	Bortezomib , Melphalan and Prednisolone
Myeloma	299	Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy
Myeloma	405	Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day
Myeloma	416	Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day
Myeloma	426	Daratumumab Monotherapy
Myeloma	435	Bortezomib Maintenance Therapy- 14 day
Myeloma	454	High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant
Myeloma	516	Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day
Myeloma	598	Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day
Myeloma	560	Daratumumab (IV), bortezomib and dexamethasone therapy
Myeloma	566	Carfilzomib and Dexamethasone (Kd) Therapy - 28 day
Myeloma	609	Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy
Myeloma	604	Daratumumab SC Monotherapy
Myeloma	595	Carfilzomib (20/70mg/m2 Once weekly) Dexamethasone (Kd) therapy - 28 day
Myeloma	601	Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy
Myeloma	643	Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day
Myeloma	695	Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy
Myeloma	703	Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy
Myeloma	755	Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy
Myeloma	752	Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy
Myeloma	756	Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy
Myeloma	780	Bortezomib,Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy
Myeloma	781	Bortezomib and Lenalidomide RVD lite consoldiation therapy
Myeloma	782	Lenalidomide RVD lite Maintenance Therapy
Neuroendocrine	320	Everolimus Monotherapy
Neuroendocrine	327	Sunitnib 37.5mg Therapy
Neuro-oncology	334	Temozolomide with RT and Adjuvant Therapy
Neuro-oncology	342	Temozolomide Recurrent Therapy
Neuro-oncology	379	Procarbazine Lomustine and VinCRIStine (PCV) Therapy
Neuro-oncology	461	Temozolomide with Radiotherapy (RT) and Adjuvant Therapy-Patients greater than 65 years
Neuro-oncology	658	Procarbazine, Lomustine and VinCRIStine (PCV) Therapy – 56 days
Neuro-oncology	742	Lomustine and Bevacizumab 5mg/kg Therapy
Paediatric Oncology	P00548	Dinutuximab beta and Isotretinoin Therapy
Paediatric Oncology	P00567	Blinatumomab Paediatric Therapy
Paediatric Oncology	P00707	Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy
Paediatric Oncology	P00748	Tisagenlecleucel
Sarcoma	100	Mifamurtide
Sarcoma	205	Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX) ® 28 days
Sarcoma	325	Sunitnib 50mg Therapy
Sarcoma	335	Imatinib Therapy-GIST
Sarcoma	374	Trabectedin Monotherapy
Sarcoma	391	DOXOrubicin (60) and Ifosfamide Therapy
Sarcoma	392	DOXOrubicin (75) and Ifosfamide Therapy
Sarcoma	420	DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle
Sarcoma	445	Pazopanib Therapy
Sarcoma	462	Pegylated Liposomal DOXOrubicin 20mg/m2 (CAELYX) ® 21 days
Sarcoma	463	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy
Sarcoma	500	DOXOrubicin 75mg/m2 Monotherapy
Sarcoma	501	Gemcitabine and DOCEtaxel Therapyi - 21 day
Sarcoma	511	Dacarbazine (1.2 g/m2) Therapy – 21 day
Sarcoma	554	VinBLAStine and Methotrexate Therapy
Sarcoma	596	Ifosfamide Etoposide (IE) Therapy
Sarcoma	675	Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals
Sarcoma	679	Infusional Ifosfamide Therapy
Sarcoma	719	SUNitinib 50mg Therapy (21 days)
Sarcoma	747	Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals
Skin/Melanoma	102	Vemurafenib Monotherapy
Skin/Melanoma	105	Ipilimumab Monotherapy
Skin/Melanoma	236	Vismodegib Monotherapy
Skin/Melanoma	237	Dabrafenib Monotherapy
Skin/Melanoma	373	Cobimetinib and Vemurafenib Therapy
Skin/Melanoma	415	Trametinib and Dabrafenib Therapy
Skin/Melanoma	431	Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy
Skin/Melanoma	455	Pembrolizumab 200mg Monotherapy
Skin/Melanoma	464	Dacarbazine Therapy
Skin/Melanoma	483	Nivolumab Monotherapy 240mg-14 day
Skin/Melanoma	484	Nivolumab Monotherapy 480mg-28day
Skin/Melanoma	535	Avelumab Monotherapy
Skin/Melanoma	551	Nivolumab 3mg Ipilimumab 1mg Therapy
Skin/Melanoma	558	Pembrolizumab 400mg Monotherapy
Skin/Melanoma	563	Encorafenib and Binimetinib Therapy
Lymphoma and Myeloma	438	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation
Leukaemia	296	Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)
Leukaemia	363	FLAG Therapy
Leukaemia	656	Acalabrutinib Monotherapy
Leukaemia	661	Midostaurin Maintenance Therapy
Leukaemia	682	Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy
Leukaemia	683	Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy
Leukaemia	788	Fedratinib Therapy
Leukaemia/BMT, Lymphoma	531	Cladribine 5 day and riTUXimab Therapy
Leukaemia/BMT, Lymphoma	534	Cladribine Weekly and riTUXimab Therapy
Lymphoma, Myeloma	536	Plerixafor and G-CSF Therapy
Lymphoma, Myeloma	795	Cyclophosphamide 1500mg/m2 For Stem Cell Mobilisation
Lymphoma	234	Brentuximab vedotin Monotherapy
Lymphoma	751	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient
Genitourinary/Gynaecology	300	Bleomycin, Etoposide and CISplatin (BEP)Therapy
Genitourinary/Gynaecology	301	Etoposide and CISplatin 20mg/m2 (EP) Therapy
Head and Neck	455	Pembrolizumab 200mg Monotherapy
Lymphoma (CAR-T on website)	606	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL
Lymphoma (CAR-T on website)	608	Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)
Leukaemia (CAR-T on website)	607	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL
Leukaemia (CAR-T on website)	686	Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL
Transplant	611	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB
Transplant	625	Fludarabine/Melphalan/Alemtuzumab-RIC-MUD
Transplant	629	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor
Transplant	630	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor
Transplant	631	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD
Transplant	635	Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD
Transplant	636	Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB
Transplant	637	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB
Transplant	638	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD
Transplant	639	Busulfan/Cyclophosphamide MAC-MUD
Transplant	641	Busulfan/Cyclophosphamide MAC-SIB
Transplant	662	Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor
Transplant	663	Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor
Lymphoma (CAR-T)	687	Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL
Lymphoma (CAR-T)	717	Axicabtagene ciloleucel (Yescarta®) (CAR-T) DLBCL and PMBCL
Breast, Genitourinary, supportive care	723	Zoledronic Acid Therapy-28 days
Breast, Genitourinary, supportive care	724	Zoledronic Acid Therapy-3 monthly
Breast, Genitourinary, supportive care	725	Zoledronic Acid Therapy-6 monthly
Breast, Genitourinary, supportive care	741	Denosumab 120mg Therapy
Tumour Agnostic	758	Larotrectinib Monotherapy - Adult
Tumour Agnostic	P00760	Larotrectinib Monotherapy - Paediatric
